| Autor: |
Malik M; Clinical Oncology Department, Lower Silesian Oncology, Pulmonology and Hematology Center, 53-413 Wroclaw, Poland., Radecka B; Department of Oncology, Institute of Medical Sciences, University of Opole, 45-040 Opole, Poland.; Department of Clinical Oncology, Tadeusz Koszarowski Cancer Center in Opole, 45-061 Opole, Poland., Gełej M; Department of Oncology, Institute of Medical Sciences, University of Opole, 45-040 Opole, Poland.; Department of Clinical Oncology, Tadeusz Koszarowski Cancer Center in Opole, 45-061 Opole, Poland., Jackowska A; Oncology and Immunooncology Clinic, Warmia and Mazury Oncology Centre, MSWiA Hospital, 10-228 Olsztyn, Poland., Filipczyk-Cisarż E; Clinical Oncology Department, Lower Silesian Oncology, Pulmonology and Hematology Center, 53-413 Wroclaw, Poland., Żurowska M; Department of Clinical Oncology and Radiotherapy, St. John Paul II Mazovia Regional Hospital in Siedlce, 08-110 Siedlce, Poland., Hetman K; Department of Clinical Oncology, West Pomeranian Oncology Center in Szczecin, 71-730 Szczecin, Poland., Foszczyńska-Kłoda M; Department of Clinical Oncology, West Pomeranian Oncology Center in Szczecin, 71-730 Szczecin, Poland., Kania-Zembaczyńska B; Department of Oncology and Oncohematology, Beskid Oncology Centre in Bielsko-Biala, 43-300 Bielsko Biala, Poland., Mańka D; Department of Oncology and Oncohematology, Beskid Oncology Centre in Bielsko-Biala, 43-300 Bielsko Biala, Poland., Orlikowska M; Oncology Department, Kociewie Health Centre, 83-200 Starogard Gdanski, Poland., Bodnar L; Department of Clinical Oncology and Radiotherapy, St. John Paul II Mazovia Regional Hospital in Siedlce, 08-110 Siedlce, Poland.; Faculty of Medical and Health Sciences, Siedlce University of Natural Sciences and Humanities, 08-110 Siedlce, Poland. |
| Abstrakt: |
In advanced-stage colorectal cancer (CRC), a strategy based on a sequence of systemic therapies brings survival benefits in most patients. Trifluridine and tipiracil hydrochloride (TT) is a chemotherapy drug effective in patients in the third- or later line setting. No highly specific biomarkers have been established for TT therapy so far. However, a systemic immune-inflammation index (SII), which is based on platelet, neutrophil and lymphocyte counts is applied to predict prognosis. In this retrospective, multicenter study, clinical data on 179 metastatic CRC patients treated with TT were collected. To evaluate factors predicting TT therapy response and overall survival, univariate logistic regression analysis was conducted. Subsequently, factors with p < 0.05 in univariate analysis were included in multivariate analysis. In the multivariate analysis of progression-free survival (PFS), three favorable parameters were significant: good to moderate histological differentiation ( p = 0.0038), carcinoembryonic antigen (CEA) < 5 ng/L ( p = 0.0316) and SII ≤ 550 ( p = 0.007). Favorable prognostic factors revealed in the multivariate analysis of overall survival (OS) were: <3 prior lines of treatment ( p = 0.02), good to moderate histological differentiation ( p = 0.0003), CEA < 5 ng/L ( p = 0.0227) and SII ≤ 550 ( p = 0.0001). Our study indicated that pre-treatment SII may be clinically useful for selecting likely responder patients and assessing the prognosis for mCRC patients treated with TT. |
